| Acne |
No |
| Active substance |
Pyridostigmine Bromide |
| Also known as |
Mestinon, Regonol |
| Aromatization |
No |
| Blood pressure |
Can cause fluctuations, typically lowering blood pressure due to vasodilation |
| Chemical name |
3-hydroxy-1-methylpyridinium bromide dimethylcarbamate |
| Dosage (medical) |
Typical starting dose for adults in the treatment of myasthenia gravis is 60 mg taken orally every 4 hours but can vary based on individual patient needs and conditions |
| Dosage (sports) |
Not applicable as it is not legally used to enhance athletic performance |
| Effects |
Improved muscle strength in patients with myasthenia gravis |
| Formula |
C9H13BrN2O2 |
| Half-life |
Approximately 1.78 to 2.25 hours |
| HBR |
No |
| Hepatotoxicity |
No |
| Lab Test |
Monitoring of cholinesterase levels may be conducted to assess efficacy and dosage requirements |
| Main action |
Inhibits the breakdown of acetylcholine, thereby increasing its concentration at neuromuscular junctions |
| Side effects |
Nausea, vomiting, diarrhea, abdominal cramps, increased salivation and sweating, muscle cramps, and twitching |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Substance class |
Acetylcholinesterase inhibitor |
| Trade name |
Mestinon, Regonol |
| Use in sports |
Not used or recommended |
| WAREHOUSE |
International Warehouse 2 |
| Water Retention |
No |
| Manufacturer |
Meda Pharma |
